期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 40, 期 14, 页码 1574-+出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1200/JCO.21.01766
关键词
-
类别
资金
- National Cancer Institute of the National Institutes of Health [U10CA180888, U10CA180819, U10CA180821, U10CA180820, UG1CA233230, UG1CA233290, UG1CA233247, UG1CA233327, UG1CA232760, UG1CA233253, UG1CA233180]
The study evaluated the efficacy of Blinatumomab as induction and consolidation therapy in older patients with Philadelphia chromosome-negative B-acute lymphoblastic leukemia. Results showed Blinatumomab had good tolerability and effectiveness in treatment, with some patients achieving complete remission, and encouraging 3-year disease-free survival and overall survival rates.
PURPOSE Chemotherapy outcomes in older patients with Philadelphia (Ph) chromosome-negative B-acute lymphoblastic leukemia (ALL) are very poor. Here, we evaluated blinatumomab as induction and consolidation therapy followed by prednisone, vincristine, 6-mercaptopurine, and methotrexate (POMP) maintenance chemotherapy in this patient population. PATIENTS AND METHODS Patients were treated at National Clinical Trial Network sites. Eligibility criteria included age >= 65 years and newly diagnosed Ph chromosome-negative B-ALL. Patients received blinatumomab as induction for one-two cycles until attainment of response (complete remission (CR) and CR with incomplete count recovery). Patients then received three cycles of consolidation with blinatumomab followed by 18 months of POMP maintenance chemotherapy. Eight doses of intrathecal methotrexate were administered as central nervous system prophylaxis. RESULTS Twenty-nine eligible patients were enrolled. The median age was 75 years, and the median bone marrow blast count at diagnosis was 87%. Cytogenetic risk was poor in 10 patients (34%), and five of 14 patients (36%) tested had the Ph-like ALL gene signature. Nineteen patients (66%; 95% CI, 46 to 82) achieved CR. Kaplan-Meier 3-year disease-free survival and overall survival estimates were 37% (95% CI, 17 to 57) and 37% (95% CI, 20 to 55), respectively. CONCLUSION Blinatumomab was well tolerated and effective in the treatment of older patients with newly diagnosed Ph chromosome-negative B-ALL, including patients with poor-risk cytogenetics. The 3-year disease-free survival and overall survival results are encouraging and suggest that this approach should be further explored.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据